Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Vanda Pharmaceuticals Inc. (VNDA)
|
Add to portfolio |
|
|
|
| Price: |
$16.55
| | Metrics |
| OS: |
57.5
|
M
| |
|
|
| Market cap: |
$952
|
M
| |
|
|
|
Net cash:
|
$489
|
M
| |
$8.51
|
per share
|
|
EV:
|
$462
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$18.1
|
M
| |
25.6
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 268.7 | 248.2 | 227.2 | 193.1 | 165.1 | 146.0 | 109.9 | 50.2 |
| Revenue growth | 8.3% | 9.2% | 17.6% | 17.0% | 13.1% | 32.8% | 119.2% | 48.0% |
| Cost of goods sold | 25.6 | 23.4 | 24.5 | 20.5 | 17.8 | 24.7 | 23.5 | 1.6 |
| Gross profit | 243.1 | 224.8 | 202.7 | 172.6 | 147.2 | 121.3 | 86.5 | 48.6 |
| Gross margin | 90.5% | 90.6% | 89.2% | 89.4% | 89.2% | 83.1% | 78.7% | 96.8% |
| Selling, general and administrative | 124.0 | 140.5 | 129.7 | 105.8 | 123.8 | 99.8 | 84.5 | 84.6 |
| Research and development | 75.4 | 55.6 | 48.6 | 43.6 | 38.5 | 29.2 | 29.1 | 19.2 |
| EBITA | 43.6 | 28.7 | 24.3 | 23.3 | -15.2 | -7.6 | -27.2 | -55.3 |
| EBITA margin | 16.2% | 11.6% | 10.7% | 12.0% | -9.2% | -5.2% | -24.8% | -110.3% |
| Amortization of intangibles | 1.5 | 1.5 | 1.5 | 1.5 | 1.8 | 10.9 | 13.0 | 2.3 |
| EBIT | 42.2 | 27.2 | 22.8 | 21.7 | -16.9 | -18.6 | -40.2 | -57.6 |
| EBIT margin | 15.7% | 11.0% | 10.0% | 11.3% | -10.2% | -12.7% | -36.6% | -114.7% |
| Pre-tax income | 42.4 | 31.7 | 29.0 | 25.3 | -15.4 | -17.9 | -39.9 | 20.2 |
| Income taxes | 9.2 | 8.3 | -86.5 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Tax rate | 21.7% | 26.3% | | 0.5% | | | 0.0% | 0.0% |
| Net income | 33.2 | 23.3 | 115.6 | 25.2 | -15.6 | -18.0 | -39.9 | 20.2 |
| Net margin | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% | -36.3% | 40.2% |
| |
| Diluted EPS | $0.58 | $0.42 | $2.11 | $0.48 | ($0.35) | ($0.41) | ($0.94) | $0.55 |
| Shares outstanding (diluted) | 56.9 | 55.2 | 54.8 | 53.0 | 44.7 | 43.4 | 42.3 | 36.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|